This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 9.24% and 115.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 133.33% and 1.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intercept (ICPT) Moves 15.0% Higher: Will This Strength Last?
by Zacks Equity Research
Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Seer, Inc. (SEER) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 14.29% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Seer (SEER) Ahead of Earnings?
by Zacks Equity Research
Seer (SEER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -26.63% in 4 Weeks, Here's Why You Should You Buy the Dip in Seer, Inc. (SEER)
by Zacks Equity Research
Seer, Inc. (SEER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Seer, Inc. (SEER) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Seer, Inc. (SEER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Seer, Inc. (SEER) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Seer, Inc. (SEER) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 0% and 6.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 4% and 67.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -212.90% and 94.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 5.13% and 17.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Stock Jumps 12.9%: Will It Continue to Soar?
by Zacks Equity Research
Seer, Inc. (SEER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 7.32% and 18.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Seer, Inc. (SEER) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Seer, Inc. (SEER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seer, Inc. (SEER) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Seer, Inc. (SEER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.